JOHN PATRICK OROHO, Executive Vice President and Chief Strategy Officer of Porzio Life Sciences, LLC, meets regularly with companies to identify sales and marketing issues and to propose solutions that streamline their practices in meeting compliance requirements of all 50 states and the District of Columbia.
Mr. Oroho is also a principal of the law firm, Porzio, Bromberg & Newman P.C., and practices in the Life Sciences Compliance and Regulatory Counseling Department. He concentrates his law practice in regulatory compliance with respect to the Prescription Drug Marketing Act (PDMA), Antikickback statute, False Claim Act, and Medicare and Medicaid fraud and abuse.
Mr. Oroho previously served as Senior Vice President and General Counsel for the PDMA Alliance, a national trade association focused on sample distribution and pharmaceutical marketing and sales compliance.
Mr. Oroho has an extensive pharmaceutical regulatory and compliance background. He spent three years as General Counsel for the company now known as QPharma, Inc.
Mr. Oroho received a J.D. from the University of Notre Dame School of Law in 1985 and a B.S. from the United States Merchant Marine Academy, where he graduated with honors in 1978.
RECENT SPEAKING ENGAGEMENTS
"Compliance for the Beginner and Expert – What You Need to Know and What You Wish You Had Known,"Expert Q&A, Interview with Alessandra Hawthorne, Head Corporate Department, Ethics and Compliance, Global Chief Ethics and Compliance Officer, Boehringer Ingelheim, 6th Annual Global Compliance Congress, London, UK, November 14, 2019.
- "Navigating State, Federal & International Transparency Disclosure Requirements," Bausch Health, Bridgewater, NJ, October 30, 2019.
"Navigating State, Federal & International Transparency Disclosure Requirements," U.S. Healthcare Compliance Certificate Program, Seton Hall Law, Newark, NJ, October 14, 2019.
- "State Drug Pricing Transparency Level-Set – Reporting and Requirements Landscape," 5th Edition Drug Pricing Transparency, Philadelphia, PA, September 19, 2019.
- Address the Recent Trends in State-By-State/City-By-City Reporting and How to Keep on the Pulse of Change," Panel Discussion, Moderator, The 13th Annual Forum on Transparency and Aggregate Spend, Washington, DC, August 13, 2019.
- "Summit Host Welcome and Anti-Trust Guideline Reminders," 16th Annual Pharmaceutical Compliance Congress, Washington, DC, April 17, 2019.
- "Address Gift Bans and Analyze State-By-State Transparency and Aggregate Spend Regulations," CBI's 12th Annual Transparency & Aggregate Spend Forum, Washington, DC, August 21, 2018.
- "Track Chair's Opening Remarks, Transparency and Aggregate Spend Section," CBI's 15th Annual Pharmaceutical Compliance Congress, Washington, DC, April 25, 2018.
- "Summit Host Welcome and Anti-Trust Guideline Reminders," CBI's 15th Annual Pharmaceutical Compliance Congress, Washington, DC, April 24, 2018.
- "U.S. Enforcement Landscape," Medical Device Regulation and MedTech Europe Code of Ethics Business Practices Summit, London, UK, April 10, 2018.
- "HCP Engagement Restrictions," Maritz Healthcare Advisory Council Meeting, Philadelphia, PA, February 27, 2018.
- "Mini Summit XVI: Compliance Considerations for Small and Mid-Sized Pharma and Medical Device Companies," 18th Annual Pharmaceutical and Medical Device Compliance Congress, Washington, DC, November 7, 2017.
- "Understanding Federal and State Reporting Laws from All Corners," Seton Hall Law School's U.S. Healthcare Compliance Certification Program, Newark, NJ, October 11, 2017.